Green Cross Health Ltd · NZX:GXH
Green Cross Health — Shareholder Meeting (July 2026)
24 slides from Green Cross Health's shareholder meeting presentation, Jul 14, 2026
Slide 1: Annual Shareholders' Meeting
Annual Shareholders’ Meeting 14 July 2026
Slide 2: Agenda
Agenda Chair’s address Group CEO’s address Resolutions and voting General Q&A GXH Annual Shareholders’ Presentation 14 July 2026 Pg 2
Slide 3: Kim Ellis | Independent Chair
Kim Ellis | Independent Chair GXH Annual Shareholders’ Presentation 14 July 2026 Pg 3
Slide 4: Rachael Newfield | Group CEO
Rachael Newfield | Group CEO GXH Annual Shareholders’ Presentation 14 July 2026 Pg 4
Slide 5: Group Revenue and Operating Profit
Group Revenue and Operating Profit GXH Operating Revenue ($m) GXH Operating Profit ($m) 546.0 45.3 523.8 34.3 38.7 31.8 503.9 493.6 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 • Revenue up 4% to $546.0m • Operating Profit of $45.3m • FY26 Revenue increase due to improved • Operating Profit increase driv
Slide 6: Group NPAT, EPS & Dividend
Group NPAT, EPS & Dividend GXH NPAT Attributable to Shareholders ($m) Dividends Per Share (cps) 34.00 * 28.00 20.4 15.0 16.0 12.0 7.00 6.00 4.50 5.75 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 Based on dividends paid during the financial year *Special dividend paid following the divestment of Community
Slide 7: Working Capital and Operating Cashflow
Working Capital and Operating Cashflow GXH Gearing Ratio (debt / debt + equity) GXH Operating Cash Flow ($m) 17.3% 52.6 54.6 10.4% 11.9% 9.4% 45.9 46.0 FY23 FY24 FY25 FY26 FY23 FY24 FY25 FY26 • Gearing ratio of 9.4% as at 31 March 2026 • Operating Cash Flow of $54.6m • Undrawn committed debt facilit
Slide 8: Divisional Performance
Divisional Performance GXH Annual Shareholders’ Presentation 14 July 2026 Pg 8
Slide 9: Pharmacy Performance
Pharmacy Performance Pharmacy Operating Revenue ($m) 380.2 370.4 360.4 363.6 • Revenue up 2% to $380.2m driven by dispensing of high-value but low-margin FY23 FY24 FY25 FY26 drugs Pharmacy Operating Profit ($m) • Operating Profit up 4% to $22.2m • Total scripts in line with prior year on a same stor
Slide 10: Funding and Pharmacist Scope
Funding and Pharmacist Scope • Care & Advice Health Hubs are well positioned to deliver the Government’s proposed extension of pharmacy services for common health conditions to commence from 2 June 2026 • Opportunity remains for further expansion of pharmacists’ scope of practice under improved fund
Slide 11: Enhancing the Customer Experience
Enhancing the Customer Experience A new pharmacy app, which is integrated with the new online customer booking system, was launched to support the clinical services provided at the Care & Advice Health Hubs A shoppable Unichem website was introduced, allowing customers to browse stock availability o
Slide 12: Investment in Store Portfolio
Investment in Store Portfolio One greenfield pharmacy opened during the period, Unichem Mount Wellington in Auckland The Beauty by Life store concept expanded to two further locations in the period, Life Queensgate and Life Albany Investment in dispensary robotics, improving operational efficiency a
Slide 13: Pharmacy Future Focus
Pharmacy Future Focus Clinical Retail Customer Network scale Cost services disciplines experience & leadership focus Expand clinical Differentiated brands Utlising technology to Leveraging our Workforce services through Care and products with improve accessibility trusted brands & productivity, marg
Slide 14: Medical Performance
Medical Performance Medical Operating Revenue ($m) 140.3 153.4 165.8 133.2 Revenue up 8% to $165.8m driven by funding uplift and incentive payments FY23 FY24 FY25 FY26 linked to national immunisation targets Medical Operating Profit ($m) Operating Profit up 33% to $26.0m driven by top line growth an
Slide 15: Medical Sale
Medical Sale All of the shares in Green Cross Health Medical, the holding company of the Medical Division To Tend Health Estimated purchase price of $270 million (subject to certain post-Completion adjustments) Proceeds used to: • - Repay bank debt in full • - Board to consider the most appropriate
Slide 16: Q&A
Q&A GXH Annual Shareholders’ Presentation 14 July 2026 Pg 16
Slide 17: Resolutions & Voting
Resolutions & Voting GXH Annual Shareholders’ Presentation 14 July 2026 Pg 17
Slide 18: Resolutions
Resolutions Resolution 1: Election of Catherine Treneman Resolution 2: Re-election of Andrew Bagnall Resolution 3: Remuneration of the Auditor Resolution 4: Special Resolution GXH Annual Shareholders’ Presentation 14 July 2026 Pg 18
Slide 19: Resolution 1: Election
Resolution 1: Election Catherine Treneman | Independent Director That Catherine Treneman be elected as a Director of Green Cross Health GXH Annual Shareholders’ Presentation 14 July 2026 Pg 19
Slide 20: Resolution 2: Re-election
Resolution 2: Re-election Andrew Bagnall | Non-Executive Director That Andrew Bagnall be re-elected as a Director of Green Cross Health GXH Annual Shareholders’ Presentation 14 July 2026 Pg 20
Slide 21: Resolution 3: Remuneration of the Auditor
Resolution 3: Remuneration of the Auditor KPMG | Auditor That the Directors be authorised to fix the remuneration of the Auditor for the ensuing year GXH Annual Shareholders’ Presentation 14 July 2026 Pg 21
Slide 22: Resolution 4: Special Resolution
Resolution 4: Special Resolution Sale of shares | Green Cross Health Medical Limited That the sale of all of the shares in Green Cross Health Medical Limited, as described in the Explanatory Notes, is approved for all purposes, including for the purpose of section 129 of the Companies Act 1993 and N
Slide 23: Q&A
Q&A GXH Annual Shareholders’ Presentation 14 July 2026 Pg 23
Slide 24: Disclaimer
Disclaimer The information in this presentation was prepared by Green Cross Health Limited (GXH) with due care and attention. However, the information is supplied in summary form and is therefore not necessarily complete, and no representation is made as to the accuracy, completeness or reliability